Absci Stock (NASDAQ:ABSI)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$3.84

52W Range

$2.45 - $6.72

50D Avg

$3.14

200D Avg

$3.91

Market Cap

$429.56M

Avg Vol (3M)

$3.83M

Beta

2.19

Div Yield

-

ABSI Company Profile

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

155

IPO Date

Jul 22, 2021

Website

ABSI Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Jun 21
Collaborative Revenue	$136.00K
Technology Development Revenue	$592.00K

Fiscal year ends in Dec 23 | Currency in USD

ABSI Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$5.72M	$5.75M	$4.78M
Operating Income	$-93.68M	$-106.75M	$-75.24M
Net Income	$-110.57M	$-104.90M	$-100.96M
EBITDA	$-79.68M	$-91.36M	$-99.77M
Basic EPS	$-1.20	$-1.15	$-1.09
Diluted EPS	$-1.20	$-1.15	$-1.09

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 12, 24 | 10:01 AM

Q2 24Aug 16, 24 | 11:50 PM

Q1 24May 14, 24 | 1:30 PM

Peer Comparison

Ticker	Company
HEPA	Hepion Pharmaceuticals, Inc.
AFMD	Affimed N.V.
RXRX	Recursion Pharmaceuticals, Inc.
RLAY	Relay Therapeutics, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
DTIL	Precision BioSciences, Inc.
SANA	Sana Biotechnology, Inc.
XFOR	X4 Pharmaceuticals, Inc.
CRBU	Caribou Biosciences, Inc.
INZY	Inozyme Pharma, Inc.
ELEV	Elevation Oncology, Inc.
ABOS	Acumen Pharmaceuticals, Inc.
ZURA	Zura Bio Limited